Deutsche Bank Upgrades Johnson & Johnson (JNJ) to Buy; Well-Diversified and Positioned

Deutsche Bank upgraded Johnson & Johnson (NYSE: JNJ) from Hold to Buy with a price target of $82.00 (from $75.00).

The firm comments, "For the past several years, JNJ has weathered through patent expirations, a general slowdown in utilization trends, and challenges with its OTC businesses. As we look ahead to 2013, we believe JNJ will see improving trends. We expect recent and new drugs to continue to drive pharma sales. A slight improvement in utilization and new products should benefit MD&D. For Consumer, J&J should continue to work through the McNeil Consent Decree and return products to market. Given these improving trends and the benefits of diversification, we believe JNJ deserves a premium to its peers."

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $70.74 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $42 at Mizuho
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy